About 600,000 bottles of Ramipril, a commonly prescribed blood pressure medication, are being recalled in the U.S. due to possible contamination tied to an unregulated supplier in India, according to the FDA. The recall includes 2.5 mg, 5 mg, and 10 mg doses distributed nationwide. The agency classified this as a Class 2 recall, meaning “the product may cause temporary or medically reversible health issues, though the risk of serious adverse consequences is remote.”

So far, no health problems have been reported, but patients are urged to check their prescriptions and consult healthcare providers if they believe their medication could be affected. The FDA stressed that people should not stop taking Ramipril without medical advice, noting that “patients are urged to review their prescriptions and consult with their healthcare providers if they suspect their medication is part of the affected batch.”

Ramipril is widely used to treat high blood pressure and reduce the risk of heart attacks, strokes, and kidney disease. Because so many patients depend on it daily, the recall has raised concern among doctors and consumers, especially those who rely on the medication to manage chronic conditions.

The incident has also drawn attention to the safety of global drug supply chains. Officials said the contaminated ingredient came from a supplier that did not follow standard U.S. regulatory practices, highlighting the need for stronger oversight and stricter quality controls. This has prompted renewed calls for better monitoring of overseas manufacturers to ensure patient safety.

Although the recall is precautionary, it serves as an important reminder of how vital quality control is in the pharmaceutical industry. Patients should contact their pharmacy or healthcare provider to confirm whether their medication is affected and discuss alternatives if needed. For the latest updates and specific batch numbers, consumers can check the FDA’s recall database or speak directly with their pharmacist.